Francesca Magrinelli

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9580583/publications.pdf

Version: 2024-02-01

623574 552653 56 839 14 26 citations g-index h-index papers 56 56 56 1345 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Pathophysiology of Motor Dysfunction in Parkinson's Disease as the Rationale for Drug Treatment and Rehabilitation. Parkinson's Disease, 2016, 2016, 1-18.	0.6	161
2	Neuropathic pain: diagnosis and treatment. Practical Neurology, 2013, 13, 292-307.	0.5	76
3	<i>RFC1</i> expansions are a common cause of idiopathic sensory neuropathy. Brain, 2021, 144, 1542-1550.	3.7	63
4	The Association between Serum Cytokines and Damage to Large and Small Nerve Fibers in Diabetic Peripheral Neuropathy. Journal of Diabetes Research, 2015, 2015, 1-7.	1.0	47
5	Risk factors of Parkinson disease. Neurology, 2020, 95, e2500-e2508.	1.5	41
6	Four-week trunk-specific exercise program decreases forward trunk flexion in Parkinson's disease: A single-blinded, randomized controlled trial. Parkinsonism and Related Disorders, 2019, 64, 268-274.	1.1	38
7	Unravelling the enigma of cortical tremor and other forms of cortical myoclonus. Brain, 2020, 143, 2653-2663.	3.7	38
8	Challenges in Clinicogenetic Correlations: One Gene – Many Phenotypes. Movement Disorders Clinical Practice, 2021, 8, 299-310.	0.8	34
9	Dissecting the Phenotype and Genotype of <scp><i>PLA2G6</i></scp> â€Related Parkinsonism. Movement Disorders, 2022, 37, 148-161.	2.2	32
10	Immunoglobulin G for the Treatment of Chronic Pain: Report of an Expert Workshop. Pain Medicine, 2014, 15, 1072-1082.	0.9	22
11	The spectrum of Charcot-Marie-Tooth disease due to myelin protein zero: An electrodiagnostic, nerve ultrasound and histological study. Clinical Neurophysiology, 2018, 129, 21-32.	0.7	21
12	Expanding the Spectrum of Movement Disorders Associated With <i>C9orf72</i> Hexanucleotide Expansions. Neurology: Genetics, 2021, 7, e575.	0.9	20
13	Tremor induced by Calcineurin inhibitor immunosuppression: a single-centre observational study in kidney transplanted patients. Journal of Neurology, 2018, 265, 1676-1683.	1.8	17
14	The Italian Consensus Conference on Pain in Neurorehabilitation: rationale and methodology. Journal of Pain Research, 2016, 9, 311.	0.8	14
15	Early downregulation of hsa-miR-144-3p in serum from drug-naÃ⁻ve Parkinson's disease patients. Scientific Reports, 2022, 12, 1330.	1.6	14
16	Assessing and treating pain in movement disorders, amyotrophic lateral sclerosis, severe acquired brain injury, disorders of consciousness, dementia, oncology and neuroinfectivology. Evidence and recommendations from the Italian Consensus Conference on Pain in Neurorehabilitation. European Journal of Physical and Rehabilitation Medicine, 2016, 52, 841-854.	1.1	14
17	Isolated and combined genetic tremor syndromes: a critical appraisal based on the 2018 MDS criteria. Parkinsonism and Related Disorders, 2020, 77, 121-140.	1.1	13
18	Restless Legs Syndrome: Known Knowns and Known Unknowns. Brain Sciences, 2022, 12, 118.	1.1	13

#	Article	IF	CITATIONS
19	Relationship between risk and protective factors and clinical features of Parkinson's disease. Parkinsonism and Related Disorders, 2022, 98, 80-85.	1.1	12
20	Voxel-based morphometry and task functional magnetic resonance imaging in essential tremor: evidence for a disrupted brain network. Scientific Reports, 2020, 10, 15061.	1.6	11
21	Effect of 5% Lidocaine Medicated Plaster on Pain Intensity and Paroxysms in Classical Trigeminal Neuralgia. Annals of Pharmacotherapy, 2014, 48, 1521-1524.	0.9	10
22	Longâ€Term Response of Neuropathic Pain to Intravenous Immunoglobulin in Relapsing Diabetic Lumbosacral Radiculoplexus Neuropathy. A Case Report. Pain Practice, 2014, 14, E85-90.	0.9	10
23	Xâ€Linked Parkinsonism: Phenotypic and Genetic Heterogeneity. Movement Disorders, 2021, 36, 1511-1525.	2.2	10
24	Pharmacological treatment for familial amyloid polyneuropathy. The Cochrane Library, 2020, 4, CD012395.	1.5	8
25	Movement Disorders and Liver Disease. Movement Disorders Clinical Practice, 2021, 8, 828-842.	0.8	7
26	Heterozygous <scp><i>EIF2AK2</i></scp> Variant Causes Adolescenceâ€Onset Generalized Dystonia Partially Responsive to <scp>DBS</scp> . Movement Disorders Clinical Practice, 2022, 9, 268-271.	0.8	7
27	Twelveâ€year Followâ€up of A Large Italian Family with Atypical Phenotypes of DYT1â€dystonia. Movement Disorders Clinical Practice, 2019, 6, 166-170.	0.8	6
28	Psychiatric Manifestations of <scp><i>ATP13A2</i></scp> Mutations. Movement Disorders Clinical Practice, 2020, 7, 838-841.	0.8	6
29	Upper camptocormia in Parkinson's disease: Neurophysiological and imaging findings of both central and peripheral pathophysiological mechanisms. Parkinsonism and Related Disorders, 2020, 71, 28-34.	1.1	6
30	Childhoodâ€Onset Chorea Caused by a Recurrent De Novo <i>DRD2</i> Variant. Movement Disorders, 2021, 36, 1472-1473.	2.2	6
31	Biallelic variants in <scp><i>ZNF142</i></scp> lead to a syndromic neurodevelopmental disorder. Clinical Genetics, 2022, 102, 98-109.	1.0	6
32	Criss-cross gait. Neurology, 2020, 95, 500-501.	1.5	5
33	Lateâ€Onset Chorea in JAK2 â€Associated Essential Thrombocythemia. Movement Disorders Clinical Practice, 2021, 8, 145-148.	0.8	5
34	Huntington disease-like phenotype in a patient with ANO3 mutation. Parkinsonism and Related Disorders, 2021, 90, 120-122.	1.1	5
35	Biallelic Lossâ€ofâ€Function NDUFA12 Variants Cause a Wide Phenotypic Spectrum from Leigh/Leighâ€Like Syndrome to Isolated Optic Atrophy. Movement Disorders Clinical Practice, 2022, 9, 218-228.	0.8	5
36	Reply to: Juvenile <i>PLA2G6</i> â€parkinsonism due to Indian †Asian†p.R741Q mutation, and response to STN DBS. Movement Disorders, 2022, 37, 658-662.	2.2	5

#	Article	IF	Citations
37	A new family with GLRB-related hyperekplexia showing chorea in homo- and heterozygous variant carriers. Parkinsonism and Related Disorders, 2020, 79, 97-99.	1.1	4
38	Huntington disease like 2 (HDL-2) with parkinsonism and abnormal DAT-SPECT – A novel observation. Parkinsonism and Related Disorders, 2020, 71, 46-48.	1.1	4
39	Diagnosing and assessing pain in neurorehabilitation: from translational research to the clinical setting. Evidence and recommendations from the Italian Consensus Conference on Pain in Neurorehabilitation. European Journal of Physical and Rehabilitation Medicine, 2016, 52, 717-729.	1.1	4
40	Paroxysmal, exercise-induced, diurnally fluctuating dystonia: Expanding the phenotype of SPG8. Parkinsonism and Related Disorders, 2021, 85, 26-28.	1.1	3
41	No evidence of a neuropathic origin in hemiplegic shoulder pain. Pain, 2013, 154, 958-959.	2.0	2
42	Diagnostic and Therapeutic Pitfalls in Considering Chronic Pain as a Disease. Pain Medicine, 2014, 15, 1640-1642.	0.9	2
43	Periodic thigh pain from radicular endometriosis. Practical Neurology, 2014, 14, 351-353.	0.5	2
44	Diagnostic methods and emerging treatments for adult neuronal ceroid lipofuscinoses (Kufs disease). Expert Opinion on Orphan Drugs, 2017, 5, 487-501.	0.5	2
45	Teaching Video Neuro <i>Images</i> : Bent spine syndrome as an early presentation of late-onset Pompe disease. Neurology, 2017, 89, e21-e22.	1.5	2
46	Pharmacological treatment for familial amyloid neuropathy. The Cochrane Library, 0, , .	1.5	1
47	Ciliary Dysfunction: The Hairy Explanation of Normal Pressure Hydrocephalus?. Movement Disorders Clinical Practice, 2020, 7, 30-31.	0.8	1
48	Reply: Pentameric repeat expansions: cortical myoclonus or cortical tremor? and Cortical tremor: a tantalizing conundrum between cortex and cerebellum. Brain, 2020, 143, e88-e88.	3.7	1
49	The Need to Tic. Movement Disorders Clinical Practice, 2020, 7, 863-864.	0.8	1
50	Throatâ€Clearing Vocalizations in Primary Brain Calcification Syndromes. Movement Disorders Clinical Practice, 2021, 8, 627-630.	0.8	1
51	Breakthrough News in Adenoviral Vectorâ€Mediated <scp>AADC</scp> Gene Therapy: Lessons from the Success in <scp>AADC</scp> Deficiency and Possible Future Applications. Movement Disorders Clinical Practice, 0, , .	0.8	1
52	Letter to the Editor. Pain, 2014, 155, 201-202.	2.0	0
53	Toward an Early Realâ€Time Quakingâ€Induced Conversion–Based Diagnostic Biomarker for Lewy Body–Related Synucleinopathies. Movement Disorders Clinical Practice, 2020, 7, 780-781.	0.8	0
54	A 58â€yearâ€old man with Bâ€cell chronic lymphocytic leukemia and multiple strokes. Brain Pathology, 2021, 31, e13004.	2.1	0

#	Article	lF	CITATIONS
55	Abnormal <scp>DaTscan</scp> in <scp>GM1</scp> â€gangliosidosis type <scp>III</scp> manifesting with dystoniaâ€parkinsonism. Movement Disorders Clinical Practice, 0, , .	0.8	O
56	<i>PRKRAP1</i> and Other Pseudogenes in Movement Disorders: The Troublemakers in Genetic Analyses Are More Than Genomic Fossils. Movement Disorders Clinical Practice, 0, , .	0.8	0